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Abstract The objective of this study was to confirm that weight loss after treatment with
mitratapide (Yarvitan®) is loss of adipose tissue. Obese dogs were treated with the
recommended treatment schedule of mitratapide. Dual-energy X-ray absorptiometry
(DEXA) was done before and after the treatment schedule. Body weight, feed consumption
and pelvic circumference were recorded and a glucose tolerance test was performed. Dual-
energy X-ray absorptiometry measurements showed an impressive loss of fat tissue,
corresponding to a mean loss of approximately 41.6% of the body fat mass recorded before
treatment. After treatment with mitratapide, the mean body fat percentage had returned
within the normal range. At the end of the study, the dogs had lost on average 14.2% of
their body weight and 15.2% of their pelvic circumference compared to baseline. The
results also suggest that losing weight with mitratapide might help to reverse insulin
resistance.
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Introduction
Canine obesity is the most common form of malnutrition encountered in small animal practice
in the western world (Burkholder and Toll 1997). Obesity is caused by an energy intake in
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Munich, Sankt-Hubertus-Strasse 12, 85764 Oberschleissheim, Germanyexcess of the requirement, resulting in a positive energy balance and accumulation of adipose
tissue (body fat). Incidence rates are estimated around 20–41% (Edney and Smith 1986;
Burkholder and Bauer 1998; McGreevy et al. 2005) and are following the same rising trend
as human obesity. Overweight and obesity have detrimental effects on general health
(Burkholder and Toll 1997). Typical consequences and co-morbidities of overweight and
obesity are diabetes mellitus, osteoarthritis, respiratory problems, cardiovascular disease,
neoplasia, hepatic disease, anesthetic complications and dermatology problems (Burkholder
and Toll 1997). Specific studies have also indicated that overweight and obesity have a direct
impact on longevity (Kealy et al. 2002;L a w l e re ta l .2005).
In human medicine, numerous studies illustrate the health benefit of weight loss (Wing
et al. 1987; Goldstein 1992; Mertens and Van Gaal 2000; Pi-Sunyer 1996). Even modest
weight loss has been demonstrated to provide a clear health benefit. The number of studies
on this subject in dogs is rather limited, but the general principles can be extrapolated from
human data.
Precise measurements of body composition are an added value in studies of obesity and
other nutritional disorders. The three-compartment model using dual-energy X-ray
absorptiometry (DEXA) shows a good and close correlation with dissection and fat
analysis. DEXA can estimate three body compartments consisting of fat mass, lean body
mass and bone (Speakman et al. 2001).
Treatment of canine overweight and obesity traditionally consists of dietary management
in combination with exercise (Burkholder and Toll 1997, Burkholder and Bauer 1998).
However, this requires long-term motivation of the owner and because there is no short-term
visible effect, it might be rather frustrating. Recently a new product (Yarvitan® 5 mg/ml,
Janssen Pharmaceutica NV, Beerse, Belgium) containing mitratapide as active ingredient was
approved in the EU for the management of overweight and obesity in dogs. Mitratapide
belongs to the class of microsomal triglyceride transfer protein (MTP) inhibitors. Orally
administered mitratapide inhibits microsomal triglyceride transfer protein at the level of the
enterocytes resulting in a decreased uptake of dietary lipids.
The objective of this study was to compare the body composition of obese Beagle dogs
before and after treatment with mitratapide by means of DEXA. Body weight, feed
consumption, pelvic circumference and glucose tolerance were also evaluated during the
experiment.
Material and methods
Investigational animals
Six intact female Beagles were included in this experiment. The animals were between two
and six years of age. Five months prior to the start of the study, the dogs were put on a high
fat diet and were fed ad libitum during three hours a day. At the start of the treatment, they
were obese, but otherwise healthy with a body weight of at least 20% above their ideal
body weight. The dogs were housed in cages in groups of two animals. During feeding,
they were housed individually. During approximately four hours per day, the dogs were
kept outdoors in kennels in groups of two to four animals. The level of exercise during the
study was not higher than before the study. The dogs had free access to drinking water
throughout the entire experiment.
The study was conducted according to all German regulations concerning ethics and
with the utmost respect for animal welfare under constant veterinary supervision.
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This study was a longitudinal study with six dogs and comprised of a mitratapide treatment
schedule (8 weeks). The study was designed in such a way that each dog served as its own
control on the basis of baseline values (body weight, DEXA, feed consumption and pelvic
circumference) and historical values (insulin/glucose). The mitratapide treatment schedule
was as follows: the dogs were treated with mitratapide oral solution (Yarvitan® 5 mg/ml;
Janssen Pharmaceutica NV, Beerse, Belgium) at the therapeutic daily dose of 0.63 mg/kg/
day. All dogs were treated once daily for two times 21 consecutive days (3 weeks) with an
intermediate period of 14 consecutive days (2 weeks) without treatment.
During the first three weeks of the mitratapide treatment schedule, the dogs were fed ad
libitum a standard dry feed (Frolic™, Mars, Germany, metabolizable energy (ME)
3240 kcal/kg) during three hours a day. Afterwards the dogs received an amount of feed
in accordance with their maintenance energy requirements (MER) during three hours a day
until the end of the study. Being seriously overweight the dogs were considered inactive
dogs. MER was calculated using the recommendations for inactive dogs (95 kcal/kg body
weight
0.75, NRC 2006) based on the ideal body weight.
Evaluation criteria
DEXA was performed under anaesthesia to assess the dog’s body composition on Day -1
and Day 56. The whole body was examined ventrodorsally (Fig. 1).
The body weight of each dog was recorded on Day -2, 1, 21, 35, 36 and 56. Pelvic
circumference was measured on Day -1, 21, 35 and 56. This was done with a measuring
tape with an accuracy of 0.1 cm. Pelvic circumference is a morphometric measure that has
been demonstrated to be well correlated with the percentage of body fat in dogs
(Burkholder and Toll 1997).
A glucose tolerance test and measurement of insulin levels was performed on Day -2 and
Day 55. The dogs were injected intravenously with a 40% glucose solution (1 g/kg body
weight, Fa. Delta Select GmbH, Dreieich, Germany). Before injection and 15, 30, 45 and
60 minutes after injection each time two blood samples were taken. One blood sample was
used to analyse glucose (Hitachi 911 Chemistry Analyzer, Roche). Serum from the other
Fig. 1 Experimental setup for
DEXA measurements in the
dog
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calculated according to Belfiore et al. (2001).
Daily feed uptake of each dog was recorded and all dogs were observed from Day -2
until Day 56 for abnormal behaviour and adverse events.
Statistical analysis
The experimental unit was each individual dog. The statistical tests were two-sided with a
significance level of 5%. Non-parameteric tests were most appropriate for parameters
expressed as scores and for parameters expressed on a continuous scale, in view of the
number of dogs in the study. Intra-statistical comparisons were applied on the individual
values by comparisons between the baseline (Day -2 or Day -1) and Day 56 of the
experiment by means of Wilcoxon Signed Rank test.
Table 1 DEXA measurements and statistical comparison
Period Fat mass [g] Lean body mass [g] Bone mineral
content [g]
Baseline (Day -1) Mean ± SD 5824±1391 12272±940 605±43
Median (Min–Max) 5965 (4148–7447) 12018 (11266–13912) 597 (522–674)
End study (Day 56) Mean ± SD 3398±1339 11923±665 582±32
Median (Min–Max) 2718 (2173–5507) 11685 (11348–13068) 569 (553–635)
P-value (Day -1 vs Day 56) 0.0313 0.3125 0.0625
Fig. 2 DEXA outprint of the
body composition of a dog be-
fore the start of the mitratapide
treatment schedule (a) and at the
end of the mitratapide treatment
schedule (b)
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DEXA measurements (Table 1, Fig. 2) show impressively how the fat mass declined
whereas the bone and lean body mass were hardly affected. The dogs lost a clinically
relevant amount (g) of fat mass during the trial, corresponding to a loss of approximately
41.6% of their initial body fat mass. The percentage of body fat (Fig. 3) after the
mitratapide treatment schedule is significantly lower compared to Day -1 (p=0.0313).
Table 2 clearly shows that the mean body weight decreased over time compared to
baseline. The mean weight loss of the dogs at the end treatment compared to baseline was
14.2% (range: 8.0%–23.1%; Fig. 4) and this was statistically significant (p=0.0313). In
Table 2 it is also shown that the mean pelvic circumference decreased over time compared
to baseline. The decrease of pelvic circumference (15.2%, Fig. 4) at the end of treatment
was also statistically significant (p=0.0313) compared to baseline.
The glucose tolerance test showed that five out of six dogs had decreased insulin
sensitivity at baseline. After the mitratapide treatment schedule, in four of these five dogs,
an increase of insulin sensitivity was noticed (Table 3, Fig. 5).
Records were made of the individual feed uptake of each animal. It was noticed that
during the study, the dogs ate less during periods with mitratapide treatment than during the
two-week treatment-free interval (Fig. 6).
Fig. 3 Mean (%) DEXA measurements (fat mass, lean body mass, bone) versus total before and after the
treatment schedule
Table 2 Body weight, body fat and pelvic circumference data
Parameter Baseline (Day -2) End study (Day 56)
Body weight (kg) Mean ± SD 18.3±2.13 15.7±1.71
Median (Min–Max) 17.8 (16.3–21.8) 15.0 (14.4–18.9)
Weight loss (%) Mean ± SD - 14.2±4.89
Median (Min–Max) - 13.5 (8.0–23.1)
Mean body fat (%) vs. total Mean ± SD 30.8±4.78 20.9±5.98
Median (Min–Max) 32.2 (25.0–36.1) 18.3 (14.4–28.8)
Pelvic circumference (cm) Mean ± SD 58.7±4.37 49.9±7.81
Median (Min–Max) 58.5 (54.0–64.0) 46.0 (43.5–63.0)
Pelvic circumference loss (%) Mean ± SD - 15.2±8.29
Median (Min–Max) - 16.7 (1.6–25.0)
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to time during treatment. Incidental vomiting was recognized once; no tracking to an
individual was possible, though. Such observations were also made during periods without
treatment. There was one case of otitis externa and one case of pseudopregnancy.
Discussion
The functions of body fat have traditionally been understood as energy storage, thermal
insulation and structural support for some organs. However, it has recently been shown that
adipose tissue is very metabolically active, produces several hormones and constitutes the
largest endocrine organ in the body (Armstrong and Churchill 2008; Greco 2008). Both the
amount and distribution of adipose tissue plays a role in insulin resistance and other obesity
related disorders. Returning dogs to optimal body condition and normalizing the percentage
body fat, i.e. between 12.3 and 27.5% (Laflamme 1997), will therefore significantly
improve control of many obesity related diseases.
The primary objective of this study was to demonstrate that weight loss after treatment
with mitratapide is loss of adipose tissue. The measurements of body composition using
DEXA showed an impressive, clinically relevant reduction of body fat in all dogs (41.6%).
After the mitratapide treatment schedule, the mean body fat percentage had returned within
the normal range (i.e. between 12.3 and 27.5% body fat). This was the case in four out of
six dogs. The two other dogs had a fat percentage of 28% and 28.8%, respectively, which is
only slightly higher than the normal range. These two dogs, however, had a much higher fat
percentage than the other dogs at the start of the study. Lean body mass and bone mineral
content remained more or less constant. These DEXA results show that mitratapide does
not induce weight loss by reduction of lean tissue but by reduction of fat tissue. These
Fig. 4 Mean body weight loss
(%) ± SD and mean pelvic
circumference loss (%) ± SD
over time
Table 3 Insulin sensitivity index
Historical data (ideal BW) Start study Day -2 (obese) End of treatment Day 56
Mean ± SD 1.04±0.169 0.75±0.271 0.91±0.201
Median (Min–Max) 1.02 (0.8–1.3) 0.71 (0.4–1.1) 0.92 (0.6–1.2)
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dogs responding to treatment as reflected by all evaluated parameters.
The body measurement parameters, i.e. body weight and pelvic circumference at the end
of the study, demonstrate a clinically relevant and statistically significant loss of body
weight (14.2%, range 8.0%–23.1%) and pelvic circumference (15.2%, range 1.6%–25.0%)
compared to baseline.
The lower feed consumption observed during the mitratapide treatment was expected
and is related to the mode of action of MTP inhibitors. Mitratapide blocks the microsomal
triglyceride transfer protein that is normally involved in the absorption of dietary fats. By
inhibiting this protein, mitratapide reduces the amount of fat absorbed through the
intestines. Fat sequestered in the enterocyte is also believed to cause the release into
the circulation of gastrointestinal peptides associated with satiety (Wren et al. 2007). The
weight reduction after treatment is related to the dual action of mitratapide, namely
decreased uptake of dietary lipids and decreased appetite.
Glucose tolerance tests at baseline showed for five obese dogs impaired insulin
sensitivity compared to historical glucose tolerance test results in the same dogs with ideal
body weight. This is an expected effect of obesity (Goschke 1977). After the mitratapide
treatment schedule, insulin sensitivity was increased again in four out of the five dogs.
These data suggest that obese dogs with insulin resistance may benefit from weight loss
(Leray et al. 2008).
Fig. 5 Insulin sensitivity before
and after treatment with mitrata-
pide (Value: 1 = normal,
<1 = decreased insulin sensitivity
(Belfiore et al. 2001))
Fig. 6 Mean feed consumption ±
SD before, during and at the
end of the mitratapide treatment
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hormones (adipokines, leptin, resistin) (Greco 2008). Leptin plays a role in the pathogenesis
of articular degenerative diseases such as osteoarthritis (Lago et al. 2008). In humans was
recently demonstrated that obesity has a significant impact on the musculoskeletal system
being associated with both degenerative and inflammatory conditions (Anandacoomarasamy
et al. 2009). Thus, mechanical stress together with biochemical factors is thought to
contribute to the onset of osteoarthritis. Mitratapide treatment was demonstrated to
reduce significant weight loss and normalizes the percentage body fat. This may be
beneficial not only in obese dogs with osteoarthritis but may also prevent the onset of
osteoarthritis in overweight and obese dogs and is therefore considered to produce a
significant health benefit.
Reduced faeces quality and vomiting is considered non-related to the treatment because
it also occurred during non-treatment periods. The case of pseudo-pregnancy is unlikely to
be related to mitratapide treatment. Neither negative energy balance nor reduced fat
absorption is associated with pseudopregnancy. In addition, in our colony pseudopreg-
nancies occur occasionally in bitches independent of treatment with mitratapide. The latter
is also true for otitis externa. However, excess adipose tissue is known to be associated with
reduced immunity (Dixit 2008) what might be a factor in this case.
This study demonstrated that the application of mitratapide treatment is safe for the
animal. During the study no serious adverse reactions were seen.
Conclusions
From this study it can be concluded that weight loss induced by the treatment of obese
dogs with mitratapide is the result of a loss of adipose tissue. After a treatment schedule
with mitratapide, the body fat percentage of obese dogs had returned within the normal
range. The amount of lean tissue and mineral bone content is hardly affected. As obesity
is one of the most common underlying causes of osteoarthritis and several hormones
produced by adipose tissue are known to play a major role in the occurrence of
comorbidities of obesity, normalizing the percentage of body fat will produce a sig-
nificant health benefit.
This study also suggested that in obese dogs with marked insulin resistance, losing
weight with mitratapide might help to reverse the insulin resistance.
Open Access This article is distributed under the terms of the Creative Commons Attribution
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